OOIR: Observatory of International Research

Papers

(The H4-Index of Annals of the Rheumatic Diseases is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Response to: ‘Successful treatment of plasma exchange for refractory systemic juvenile idiopathic arthritis complicated with macrophage activation syndrome and severe lung disease’ by Sato et al	874
Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia	532
Response to: ‘Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience' by Pineda-Sic et al	531
Correspondence on ‘Jan Gösta Waldenström and rheumatology‘	519
Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumat	384
Short duration antibiotic therapy for native joint arthritis caused by Neisseria infection?	306
Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al	296
Response to: ‘Correspondence on: irritable bowel syndrome symptoms in axial spondyloarthritis more common than among healthy controls: is it an overlooked comorbidity?' by Proft et al.	290
Response to: ‘Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors’ by Jovani et al	287
Response to: ‘Correspondence on ‘Variants in urate transporters, ADH1B, GCKR and MEPE genes associated with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asympt	285
Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation	281
Response to: ‘Off-label use of tofacitinib: a potential treatment option for SAPHO syndrome’ by Xie et al	250
Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19	247
Exaggerated neutrophil extracellular trap formation in Kawasaki disease: a key phenomenon behind the outbreak in western countries?	229
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al	221
Dysregulation of immune checkpoint molecules as a characteristic of autoimmune congenital heart block	219
Correspondence on ‘Standardisation of myositis-specific antibodies: where are we today?’	215
Response to: ‘Anti-Ku antibodies: important points to consider’ by Mahler et al	213
Response to: ‘Correspondence to ‘Slope sign': a feature of large vessel vasculitis?' by Milchert et al	213
AB0441 IMPACT OF URICEMIA ON PSORIATIC ARTHRITIS, AND ON SAFETY AND CLINICAL RESPONSE TO UPADACITINIB AND ADALIMUMAB: POST-HOC ANALYSIS OF PHASE III STUDIES	203
POS0993 ELEVATED INTRACELLULAR IFN SIGNALING BY T AND B CELLS BUT UNALTERED B CELL DISTRIBUTION IS A CHARACTERISTIC OF ANTI-SSA POSITIVE ASYMPTOMATIC WOMEN AT-RISK FOR CONGENITAL HEART BLOCK	188
POS0532 DEUCRAVACITINIB, AN ORAL, ALLOSTERIC, TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT-REPORTED OUTCOMES IN A PHASE 2 TRIAL	186
OP0057 EVALUATION OF SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) COHORT	184
POS0389 LOW INCIDENCE OF LATE-ONSET GCA DURING THE FIRST YEAR IN PATIENTS WITH POLYMYALGIA RHEUMATICA — AN IMAGING-BASED STUDY	179
AB0372 PAIN SYNDROME, PHYSICAL ACTIVITY AND QUALITY OF LIFE IN WOMEN WITH OSTEOARTHRITIS AND SARCOPENIA	178

POS1021 THE EFFECT OF CANNABIDIOL ON QUANTITATIVE SENSORY TESTING PARAMETERS IN PATIENTS WITH HAND OSTEOARTHRITIS AND PSORIATIC ARTHRITIS: A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL	172
POS0916 DRUG SURVIVAL OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS: DATA FROM FIVE COUNTRIES OF LATIN AMERICA	165
POS1430 WATCH OUT FOR THE INFLAMMATORY RESPONSE IN AUTOIMMUNE DISEASES WITH INTERSTITIAL PNEUMONIA. A RETROSPECTIVE STUDY	165
POS1035 FORCED VITAL CAPACITY TRAJECTORIES AND RISK OF LUNG TRANSPLANT AND ILD-RELATED MORTALITY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE	164
AB0503 SELF-REPORTED CLINICAL AND PSYCHOLOGICAL FACTORS ASSOCIATED WITH ADHERENCE: RESULTS FROM THE BRAGGSS COHORT	160
POS1478-HPR ANALYSIS OF MEDICATION USAGE AND MONTHLY COSTS IN HOSPITALIZED PATIENTS WITH RHEUMATIC DISEASES: A RETROSPECTIVE OBSERVATIONAL STUDY	154
AB0738 EXPRESSION AND ROLE OF THE LNCRNA RP11-184M15.1 IN THE MYELOID COMPARTMENT DURING INFLAMMATION	153
AB0183 CARDIAC EFFECTS OF THE ARTHRITIS/HEART FAILURE COMORBIDITY	143
AB1016 SERUM CXCL-13 LEVELS ARE ASSOCIATED WITH ACTIVE NEUROLOGICAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	141
AB1151 CIRCULATING CTHRC1 LEVELS ARE ASSOCIATED WITH DISEASE SEVERITY AND PREDICT SURVIVAL IN SYSTEMIC SCLEROSIS	140
AB1598-HPR MOTHERHOOD AND FAMILY PLANNING BELIEFS IN WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES	133
AB1028 EFFECT OF RENIN-ANGIOTENSIN-SYSTEM INHIBITORS ON RENAL REMISSION IN LUPUS NEPHRITIS: A REAL-WORLD STUDY	133
AB1649-PARE BARRIERS TO DIAGNOSIS, TREATMENT, AND CARE FOR IgG4-RELATED DISEASE: DATA FROM A LARGE COHORT OF ITALIAN PATIENTS	129
OP0120 EFFECTIVENESS AND COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPONDYLOARTHRITIS (TeleSpA-STUDY): A PRAGMATIC MULTICENTRE RANDOMISED CONTROLLED	127
AB0661 TOFACITINIB PLUS IGURATIMOD IN RHEUMATOID ARTHRITIS-RELATED PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE: 13 CASES FROM A SINGLE CENTRE IN CHINA	126
AB0462 ONE-YEAR RETENTION RATE OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS. DATA OF THE SPANISH BIOBADASER REGISTRY	120
AB0943 ASSESSING THE IMPACT OF SARCOPENIA IN AXIAL SPONDYLOARTHRITIS	119
AB0666 CYCLING VERSUS SWITCHING AFTER INEFFECTIVENESS OF FIRST TUMOR NECROSIS FACTOR INHIBITOR DURING FIRST YEAR OF THERAPY - DEMOGRAPHIC AND CLINICAL DIFFERENCES IN RHEUMATOID ARTHRITIS	115
AB0916 EFFECTIVENESS OF A PERSONALIZED PHYSICAL TRAINING PROGRAM ON DISEASE ACTIVITY AND AEROBIC CAPACITY IN axSpA: A RANDOMIZED CONTROLLED STUDY	112
AB1225 COMPARISON OF THE ACUTE EFFECTS OF INTRAVENOUS ILOPROST ON FINGER POWER DOPPLER ULTRASOUND IN SCLERODERMA PATIENTS IN TWO INFUSION 4 WEEKS APART	111
OP0251 DURATION OF CLINICALLY MEANINGFUL ANALGESIC RESPONSE TO INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE, EMPTY, MULTILAMELLAR LIPOSOMES, IN PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS: ANALYSI	107
AB1258 EFFECTIVENESS OF DUPILUMAB ON REFRACTORY CHRONIC RHINOSINUSITIS WITH NASAL POLYPS IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A CLINICAL AND CYTOLOGICAL STUDY	106
OP0012 AN INVESTIGATION OF THE DIFFERENTIAL THERAPEUTIC EFFECTS OF ROMOSOZUMAB ON POSTMENOPAUSAL OSTEOPOROSIS PATIENTS WITH OR WITHOUT RHEUMATOID ARTHRITIS COMPLICATIONS: A CASE-CONTROL STUDY	106
AB0313 SECONDARY PREVENTION OF OSTEOPOROSIS: CLINICAL AND FUNCTIONAL PROFILE OF ELDERLY PATIENTS WITH HIP FRACTURE	105
AB0732 CELLULAR AND MOLECULAR HALLMARKS OF EARLY METHOTREXATE RESPONSE IN RA	105
AB1134 SERUM ADVANCED GLYCATION END-PRODUCTS AND THEIR SOLUBLE RECEPTOR AS POTENTIAL NEW BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS	104
POS0071 IMMUNOMODULATORY TREATMENT AND IMMUNE RESPONSES TO COVID-19 BOOSTER SHOTS IN PATIENTS WITH AUTOIMMUNE RHEUMATIC DISEASES: RESULTS FROM THE COVID-19 VACCINE RESPONSE IN RHEUMATOLOGY PATIENTS (C	102
POS0648 EFFICACY AND SAFETY OF LOW OR HIGH DOSE METHOTREXATE IN COMBINATION WITH ADALIMUMAB IN PATIENTS WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS: RESULTS FROM THE RANDOMISED, CONTROLLED MIRACLE TRIAL	101
POS1117 1-YEAR FOLLOW-UP OUTCOME OF DIFFERENT TREATMENT REGIMENS FOR LUPUS NEPHRITIS	99
POS0160-HPR IMPACT OF A SMARTPHONE DIGITAL THERAPEUTIC (DTx) APP WITH REAL-TIME FEEDBACK IN THE MANAGEMENT OF AXIAL SPONDYLOARTHRITIS (axSpA) THROUGH PHYSIOTHERAPY HOME-BASED EXERCISE PROGRAM: A PILOT	97
POS0283 DISEASE - CHARACTERISTIC CHANGES CAN ALREADY BE FOUND IN INDIVIDUALS AT RISK OF SJÖGREN’S SYNDROME – RESULTS OF THE preSStige STUDY	95
POS0344 PAROTID TRANSCRIPTOMIC NETWORKS ASSOCIATED WITH B CELL HYPERACTIVITY, AND VIRUS/IFN ACTIVITY ARE TARGETED BY LEFLUNOMIDE/HYDROXYCHLOROQUINE THERAPY IN SJÖGREN PATIENTS AND ARE CAPTURED BY A CI	94
AB0394 COMORBIDITIES IN 40.643 PSORIATIC ARTHRITIS PATIENTS ACCORDING TO GENDER: RESULTS FROM E.PULSE, THE NATIONWIDE HEALTH DATA	93
AB1126 REBAMIPIDE ATTENUATES RENAL MANIFESTATIONS VIA ANTIOXIDANT EFFECTS ON PODOCYTES IN AN ANIMAL MODEL FOR SYSTEMIC LUPUS ERYTHEMATOSUS	92
POS1001 INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELLS ALLEVIATE SJÖGREN’S SYNDROME BY MODULATING THE MATURATION PROCESS OF SPLENIC B CELLS	91
AB1620-HPR CHANGE IN THE UTILITY OF ANTINUCLEAR ANTIBODIES (ANA) FOLLOWING THE IMPLEMENTATION OF ANALYTICAL REQUEST BASED ON PATIENT PROFILE	89
AB0160 THE USE OF IL-6 INHIBITORS IN PATIENTS WITH POLYMYALGIA RHEUMATICA RECEIVING GLUCOCORTICOID THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS	88
POS0743 OPTIMIZING REFERRAL TO RHEUMATOLOGY – A NEW STRATEGY TO PREVENT REFERRAL OF PATIENTS WITH LOW LIKELIHOOD OF AN INFLAMMATORY RHEUMATIC DISEASE	88
POS0234 IMPACT OF PROPHYLACTIC TRIMETHOPRIM-SULFAMETHOXAZOLE ON THE INCIDENCE OF SERIOUS INFECTION IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS: A MULTICENTER COHORT STUDY	86
AB1272 MANAGING OF ANCA-ASSOCIATED VASCULITIS: ADHERENCE TO TREATMENT GUIDELINES AND EARLY MODIFICATIONS, ARE WE THERE YET?	86
POS0878 INFERTILITY AND THE CHANCE OF SUCCESSFUL ASSISTED REPRODUCTION TREATMENTS IN CHILDBEARING WOMEN WITH RHEUMATIC DISEASES	85
AB0073 ANTIBODY RESPONSE AND COVID-19 DISEASE AFTER SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES RECEIVING BIOLOGICAL TREATMENT	84
POS0349 SINGLE OSTEOCLAST RESORPTION ANALYSIS REVEALS AN INCREASED INTRINSIC OSTEOCLAST ACTIVITY IN RA PATIENTS	83
POS0697 OPHTHALMIC MANIFESTATIONS IN TAKAYASU ARTERITIS PATIENTS: A CROSS-SECTIONAL MONOCENTRIC STUDY	82
POS1220 MODULATING INFLAMMATION IN AN ADVANCED 3D MODEL OF RHEUMATOID ARTHRITIS SYNOVIAL TISSUE INCORPORATING FIBROBLASTS, ENDOTHELIAL CELLS AND MACROPHAGES	80
POS1377 REFINING AUTOANTIBODY PROFILES IN PATIENTS WITH RHEUMATOID ARTHRITIS – A SCANDINAVIAN STUDY ON 6900 SAMPLES	79
AB1089 CORRELATION OF AUTOANTIBODIES AND PERICARDITIS IN SLE PATIENTS	79
AB1331 DIAGNOSTIC CAPABILITY OF ANESTHETIC INTRA-ARTICULAR INJECTIONS FOR FEMOROACETABULAR IMPINGEMENT	78
POS0714 MYOCARDITIS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PATIENTS WITH MELANOMA RECEIVING IMMUNE CHECKPOINT INHIBITORS	78
AB1349 CORRELATION OF CHRONIC INFLAMMATION MARKERS WITH ULTRASOUND SIGNS OF ATHEROSCLEROTIC HEART DISEASE AND BRACHIOCEPHALIC ARTERIES LESIONS IN RHEUMATOID ARTHRITIS	76

AB0795 Are patients with ankylosing spondylitis afraid of falling compared to healthy controls?: the role of balance and posture	76
AB1019 THE EFFECTS OF THREE DIFFERENT VITAMIN D3 SUPPLEMENTATION REGIMENS IN DEFICIENT SUBJECTS ON INFLAMMATORY CYTOKINES – A RANDOMISED OPEN-LABEL PARALLEL GROUPS STUDY	76